Author: Matusali, Giulia; Colavita, Francesca; Lapa, Daniele; Meschi, Silvia; Bordi, Licia; Piselli, Pierluca; Gagliardini, Roberta; Corpolongo, Angela; Nicastri, Emanuele; Antinori, Andrea; Ippolito, Giuseppe; Capobianchi, Maria Rosaria; Castilletti, Concetta
Title: SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus Cord-id: kvr9eff1 Document date: 2021_4_10
ID: kvr9eff1
Snippet: SARS-CoV-2 serum neutralization assay represents the gold standard for assessing antibody-mediated protection in naturally infected and vaccinated individuals. In the present study, 662 serum samples collected from February 2020 to January 2021 from acute and convalescent COVID-19 patients were tested to determine neutralizing antibody (NAb) titers using a microneutralization test (MNT) for live SARS-CoV-2. Moreover, anti-SARS-CoV-2 IgG, IgA, and IgM directed against different viral antigens wer
Document: SARS-CoV-2 serum neutralization assay represents the gold standard for assessing antibody-mediated protection in naturally infected and vaccinated individuals. In the present study, 662 serum samples collected from February 2020 to January 2021 from acute and convalescent COVID-19 patients were tested to determine neutralizing antibody (NAb) titers using a microneutralization test (MNT) for live SARS-CoV-2. Moreover, anti-SARS-CoV-2 IgG, IgA, and IgM directed against different viral antigens were measured by high-throughput automated platforms. We observed higher levels of NAbs in elderly (>60 years old) individuals and in patients presenting acute respiratory distress syndrome. SARS-CoV-2 NAbs develop as soon as five days from symptom onset and, despite a decline after the second month, persist for over 11 months, showing variable dynamics. Through correlation and receiver operating characteristic (ROC) curve analysis, we set up a testing algorithm, suitable for the laboratory workload, by establishing an optimal cutoff value of anti-SARS-CoV-2 IgG for convalescent plasma donors to exclude from MNT samples foreseen to have low/negative NAb titers and ineligible for plasma donation. Overall, MNT, although cumbersome and not suitable for routine testing of large sample sizes, remains the reference tool for the assessment of antibody-mediated immunity after SARS-CoV-2 infection. Smart testing algorithms may optimize the laboratory workflow to monitor antibody-mediated protection in COVID-19 patients, plasma donors, and vaccinated individuals.
Search related documents:
Co phrase search for related documents- abbott architect and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- abbott architect and acute sars infection: 1, 2
- abbott architect and live virus: 1
- abbott architect and longitudinal analysis: 1
- abbott architect and longitudinal study: 1, 2, 3
- abbott architect and low negative: 1, 2
- abbott diagnostics and acute respiratory syndrome: 1, 2
- abbott sars and acute infection: 1, 2, 3, 4, 5, 6
- abbott sars and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
- abbott sars and acute sars infection: 1, 2, 3, 4
- abbott sars and live virus: 1, 2, 3
- abbott sars and longitudinal study: 1, 2
- abbott sars and low negative: 1
- abbott sars assay and acute infection: 1, 2, 3
- abbott sars assay and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- abbott sars assay and acute sars infection: 1, 2, 3
- abbott sars assay and live virus: 1, 2
- abbott sars assay and longitudinal study: 1
- acute ards respiratory distress syndrome and live virus: 1
Co phrase search for related documents, hyperlinks ordered by date